PCRX Pacira Biosciences Inc.

Pacira to Report Second Quarter 2020 Financial Results on Thursday August 6, 2020

Pacira to Report Second Quarter 2020 Financial Results on Thursday August 6, 2020

PARSIPPANY, N.J., July 30, 2020 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced that it will report its second quarter financial results before the open of the U.S. markets on Thursday, August 6, 2020. Following the release, the company will host a live conference call and webcast at 8:30 a.m. ET.

To participate in the conference call, dial 1-877-845-0779 and provide the passcode 3276818. International callers may dial 1-720-545-0035 and use the same passcode. In addition, a live audio of the conference call will be available as a webcast. Interested parties can access the event through the “Events” page on the Pacira website at .

For those unable to participate in the live call, a replay will be available at 1-855-859-2056 (domestic) or 1-404-537-3406 (international) using the passcode 3276818. The replay of the call will be available for one week from the date of the live call. The webcast will be available on the Pacira website for approximately two weeks following the call.

About Pacira

Pacira BioSciences, Inc. (NASDAQ: PCRX) is a leading provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for health care practitioners and their patients. The company’s long-acting local analgesic, EXPAREL® (bupivacaine liposome injectable suspension) was commercially launched in the United States in April 2012. EXPAREL utilizes DepoFoam®, a unique and proprietary product delivery technology that encapsulates drugs without altering their molecular structure, and releases them over a desired period of time. In April 2019, the company acquired the iovera⁰ system, a handheld cryoanalgesia device used to deliver precise, controlled doses of cold temperature only to targeted nerves. To learn more about Pacira, including the corporate mission to reduce overreliance on opioids, visit .

Investor Contact:

Pacira BioSciences, Inc.
Christian Pedetti, (973) 254-4387
 
EN
30/07/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Pacira Biosciences Inc.

 PRESS RELEASE

Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule...

Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BRISBANE, Calif., March 06, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients, today announced the granting of inducement awards on March 3, 2026 to three new employees under Pacira’s Amended and Restated 2014 Inducement Plan (the “Inducement Plan”) as a material inducement to each employee’s entry into employment with the company. In accordance with Nasdaq Listing Rule 5635(c)(4), ...

 PRESS RELEASE

Pacira BioSciences to Participate in Fireside Chat at the Barclays 28t...

Pacira BioSciences to Participate in Fireside Chat at the Barclays 28th Annual Global Healthcare Conference BRISBANE, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that it will participate in an analyst-led fireside chat at the Barclays 28th Annual Global Healthcare Conference at 2:30 PM ET on Wednesday, March 11, 2026 in Miami. Live audio of the event can be accessed by visiting the “Events” page of the company’s ...

 PRESS RELEASE

Pacira BioSciences Presents Two Real-World Studies from Its Innovation...

Pacira BioSciences Presents Two Real-World Studies from Its Innovations in Genicular Outcomes Registry (IGOR) -- Studies highlight the clinical effectiveness of EXPAREL for total knee arthroplasty and long-term pain management with ioveraº for patients with osteoarthritis (OA) of the knee -- -- Data presented at the American Academy of Orthopedic Surgeons 2026 Annual Meeting -- BRISBANE, Calif., March 02, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of p...

 PRESS RELEASE

Pacira BioSciences Reports Fourth Quarter and Full-Year 2025 Financial...

Pacira BioSciences Reports Fourth Quarter and Full-Year 2025 Financial Results — Record-high EXPAREL sales driven by volume growth of 7 percent, marking strongest fourth quarter performance in three years — — Conference call today at 4:30 p.m. ET — BRISBANE, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today reported financial results for the fourth quarter and full-year of 2025. “2025 was a year of disciplined execution for P...

 PRESS RELEASE

Pacira to Report 2025 Financial Results on Thursday February 26, 2026

Pacira to Report 2025 Financial Results on Thursday February 26, 2026 BRISBANE, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that it will report its fourth quarter and year ended December 31, 2025 financial results after the close of the U.S. markets on Thursday February 26, 2026. Following the release, the company will host a live conference call and webcast at 4:30 p.m. ET. For listeners who wish to participate ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch